Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Orange Co Retina Medical Group
mi
from
Santa Ana, CA
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Orange Co Retina Medical Group
mi
from
Santa Ana, CA
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Bay Area Retina Associates
mi
from
Walnut Creek, CA
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Bay Area Retina Associates
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Colorado Retina Associates
mi
from
Denver, CO
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Colorado Retina Associates
mi
from
Denver, CO
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Illinois Retina Associates
mi
from
Harvey, IL
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Illinois Retina Associates
mi
from
Harvey, IL
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
John-Kenyon American Eye Institute
mi
from
New Albany, IN
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
John-Kenyon American Eye Institute
mi
from
New Albany, IN
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Associated Retina Consultants
mi
from
Royal Oak, MI
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Associated Retina Consultants
mi
from
Royal Oak, MI
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Associated Retinal Consultants, PC
mi
from
Traverse City, MI
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Associated Retinal Consultants, PC
mi
from
Traverse City, MI
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Lifelong Vision Foundation
mi
from
Chesterfield, MO
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Lifelong Vision Foundation
mi
from
Chesterfield, MO
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Eyesight Ophthalmic Services, PA
mi
from
Portsmouth, NH
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Eyesight Ophthalmic Services, PA
mi
from
Portsmouth, NH
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
New Jersey Retina
mi
from
New Brunswick, NJ
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
New Jersey Retina
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Long Island Vitreoretinal Consultants - Long Island Retina - Hauppauge
mi
from
Great Neck, NY
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Long Island Vitreoretinal Consultants - Long Island Retina - Hauppauge
mi
from
Great Neck, NY
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Mid-Atlantic Retina
mi
from
Philadelphia, PA
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Mid-Atlantic Retina
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Texas Retina Associates, Arlington
mi
from
Arlington, TX
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Texas Retina Associates, Arlington
mi
from
Arlington, TX
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Valley Retina Institute, P.A.
mi
from
McAllen, TX
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated:  5/31/2016
Raj Maturi
mi
from
Indianapolis, IN
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
Status: Enrolling
Updated: 5/31/2016
Raj Maturi
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)
A Randomized, Controlled Study of the Safety and Efficacy of Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  5/31/2016
NJ Retina
mi
from
New Brunswick, NJ
Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)
A Randomized, Controlled Study of the Safety and Efficacy of Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 5/31/2016
NJ Retina
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
A Single Center, Randomized, Controlled, Single-Masked, Cross-Over Clinical Pilot Study to Evaluate the Reduction in the Exacerbation of the Symptoms of Dry Eye Upon Exposure to a Controlled Adverse Environment
Status: Enrolling
Updated:  6/1/2016
Andover Eye Associates
mi
from
Andover, MA
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
A Single Center, Randomized, Controlled, Single-Masked, Cross-Over Clinical Pilot Study to Evaluate the Reduction in the Exacerbation of the Symptoms of Dry Eye Upon Exposure to a Controlled Adverse Environment
Status: Enrolling
Updated: 6/1/2016
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes
Concomitant Dry Eye in Patients With Ocular Allergy: an Under Recognized and Poorly Managed Syndrome
Status: Enrolling
Updated:  6/2/2016
Schwartz Laser Eye Center
mi
from
Scottsdale, AZ
Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes
Concomitant Dry Eye in Patients With Ocular Allergy: an Under Recognized and Poorly Managed Syndrome
Status: Enrolling
Updated: 6/2/2016
Schwartz Laser Eye Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Status: Enrolling
Updated:  6/8/2016
United States, California
mi
from
Beverly Hills, CA
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Status: Enrolling
Updated: 6/8/2016
United States, California
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Status: Enrolling
Updated:  6/8/2016
Untied States, Florida
mi
from
Miami, FL
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Status: Enrolling
Updated: 6/8/2016
Untied States, Florida
mi
from
Miami, FL
Click here to add this to my saved trials
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Status: Enrolling
Updated:  6/8/2016
United States, New Hampshire
mi
from
Portsmouth, NH
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Status: Enrolling
Updated: 6/8/2016
United States, New Hampshire
mi
from
Portsmouth, NH
Click here to add this to my saved trials
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Status: Enrolling
Updated:  6/8/2016
Australia, New South Wells
mi
from
Parramatta,
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Status: Enrolling
Updated: 6/8/2016
Australia, New South Wells
mi
from
Parramatta,
Click here to add this to my saved trials
A Pilot Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
A Pilot Randomized Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
Status: Enrolling
Updated:  6/16/2016
Marshall B. Ketchum University
mi
from
Fullerton, CA
A Pilot Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
A Pilot Randomized Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
Status: Enrolling
Updated: 6/16/2016
Marshall B. Ketchum University
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Pilot Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
A Pilot Randomized Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
Status: Enrolling
Updated:  6/16/2016
The Mayo Clinic
mi
from
Rochester, MN
A Pilot Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
A Pilot Randomized Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
Status: Enrolling
Updated: 6/16/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Open Label Extension of LipoLat-CS202
An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma
Status: Enrolling
Updated:  6/16/2016
Professional Research Network
mi
from
Goose Creek, SC
Open Label Extension of LipoLat-CS202
An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma
Status: Enrolling
Updated: 6/16/2016
Professional Research Network
mi
from
Goose Creek, SC
Click here to add this to my saved trials
Clinical Evaluation of the RAVI-Guide
Clinical Evaluation of the Rapid Access Vitreal Injection Guide (RAVI-Guide)
Status: Enrolling
Updated:  6/22/2016
Froedtert and Medical College of Wisconsin Eye Institute
mi
from
Milwaukee, WI
Clinical Evaluation of the RAVI-Guide
Clinical Evaluation of the Rapid Access Vitreal Injection Guide (RAVI-Guide)
Status: Enrolling
Updated: 6/22/2016
Froedtert and Medical College of Wisconsin Eye Institute
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Observation Versus Occlusion Therapy for Intermittent Exotropia
A Randomized Clinical Trial of Observation Versus Occlusion Therapy for Intermittent Exotropia
Status: Enrolling
Updated:  6/24/2016
Southern California College of Optometry
mi
from
Fullerton, CA
Observation Versus Occlusion Therapy for Intermittent Exotropia
A Randomized Clinical Trial of Observation Versus Occlusion Therapy for Intermittent Exotropia
Status: Enrolling
Updated: 6/24/2016
Southern California College of Optometry
mi
from
Fullerton, CA
Click here to add this to my saved trials
Observation Versus Occlusion Therapy for Intermittent Exotropia
A Randomized Clinical Trial of Observation Versus Occlusion Therapy for Intermittent Exotropia
Status: Enrolling
Updated:  6/24/2016
Mayo Clinic Department of Ophthalmology
mi
from
Rochester, MN
Observation Versus Occlusion Therapy for Intermittent Exotropia
A Randomized Clinical Trial of Observation Versus Occlusion Therapy for Intermittent Exotropia
Status: Enrolling
Updated: 6/24/2016
Mayo Clinic Department of Ophthalmology
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Anaheim, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Laguna Hills, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Murrieta, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Murrieta, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
San Luis Obispo, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Denver, CO
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Denver, CO
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Englewood, CO
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Middlebury, CT
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Middlebury, CT
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
New Britain, CT
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
New Britain, CT
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Trinity, FL
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Trinity, FL
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Coeur D'Alene, ID
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Greenwood, IN
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Greenwood, IN
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
West Des Moines, IA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
West Des Moines, IA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Kansas City, KA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Shreveport, LA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Annapolis, MD
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Annapolis, MD
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Greenbelt, MD
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Greenbelt, MD
Click here to add this to my saved trials